406 related articles for article (PubMed ID: 23429668)
1. Clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus and hepatitis C virus dual infection.
Caccamo G; Saffioti F; Raimondo G
World J Gastroenterol; 2014 Oct; 20(40):14559-67. PubMed ID: 25356020
[TBL] [Abstract][Full Text] [Related]
3. Virus entry mediated by hepatitis B virus envelope proteins.
Taylor JM
World J Gastroenterol; 2013 Oct; 19(40):6730-4. PubMed ID: 24187448
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
5. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
[TBL] [Abstract][Full Text] [Related]
6. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
Beaumont E; Roingeard P
Vaccine; 2015 Feb; 33(8):973-6. PubMed ID: 25596457
[TBL] [Abstract][Full Text] [Related]
7. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
8. [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
Kalayci R; Altindiş M; Gülamber G; Demirtürk N; Akcan Y; Demirdal T
Mikrobiyol Bul; 2010 Apr; 44(2):237-43. PubMed ID: 20549958
[TBL] [Abstract][Full Text] [Related]
9. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
10. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.
Jin J; Yang JY; Liu J; Kong YY; Wang Y; Li GD
World J Gastroenterol; 2002 Jun; 8(3):505-10. PubMed ID: 12046080
[TBL] [Abstract][Full Text] [Related]
11. A hepatitis B virus causes chronic infections in equids worldwide.
Rasche A; Lehmann F; Goldmann N; Nagel M; Moreira-Soto A; Nobach D; de Oliveira Carneiro I; Osterrieder N; Greenwood AD; Steinmann E; Lukashev AN; Schuler G; Glebe D; Drexler JF;
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33723007
[TBL] [Abstract][Full Text] [Related]
12. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.
Sukowati CH; El-Khobar KE; Ie SI; Anfuso B; Muljono DH; Tiribelli C
World J Gastroenterol; 2016 Jan; 22(4):1497-512. PubMed ID: 26819517
[TBL] [Abstract][Full Text] [Related]
13. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma.
Araujo OC; Barros JJ; do Ó KM; Nabuco LC; Luz CA; Perez RM; Niel C; Villela-Nogueira CA; Araujo NM
J Med Virol; 2014 Feb; 86(2):217-23. PubMed ID: 24338810
[TBL] [Abstract][Full Text] [Related]
14. Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity.
Piconese S; Cammarata I; Barnaba V
J Autoimmun; 2018 Dec; 95():58-68. PubMed ID: 30509387
[TBL] [Abstract][Full Text] [Related]
15. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
Prentoe J; Bukh J
Front Immunol; 2018; 9():2146. PubMed ID: 30319614
[TBL] [Abstract][Full Text] [Related]
16. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
18. Low-level hepatitis C viremia and humoral immune response to NS4 in chronic hepatitis B virus-hepatitis C virus coinfection.
Chu CM; Sheen IS; Liaw YF
Scand J Gastroenterol; 2004 Aug; 39(8):778-82. PubMed ID: 15513365
[TBL] [Abstract][Full Text] [Related]
19. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
20. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.
Barth H; Schnober EK; Zhang F; Linhardt RJ; Depla E; Boson B; Cosset FL; Patel AH; Blum HE; Baumert TF
J Virol; 2006 Nov; 80(21):10579-90. PubMed ID: 16928753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
